In recent months, Vor Biopharma closed a US$424.83 million shelf registration, repriced employee stock options, and reported positive late-stage clinical data for its autoimmune drug candidate ...
Vor Bio granted Dr. Qing Zuraw stock options and RSUs as part of her employment package, effective July 17, 2025. Vor Bio, a biotechnology company focused on treating autoimmune diseases, announced ...
Vor Bio grants CEO Jean-Paul Kress an option to purchase 83.3 million shares at $0.89, vesting over four years. Vor Bio, a biotechnology company specializing in autoimmune disease treatments, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback